- Home
- AIM
as 01-17-2025 4:00pm EST
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
| Founded: | 1966 | Country: | United States |
| Employees: | N/A | City: | OCALA |
| Market Cap: | 15.9M | IPO Year: | N/A |
| Target Price: | $2.75 | AVG Volume (30 days): | 672.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.16 - $0.62 | Next Earning Date: | 11-15-2024 |
| Revenue: | $190,000 | Revenue Growth: | -1.55% |
| Revenue Growth (this year): | -27.5% | Revenue Growth (next year): | 1693.10% |
Stock Insider Trading Activity of AIM ImmunoTech Inc. (AIM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MITCHELL WILLIAM M | AIM | Director | Dec 19 '24 | Sell | $0.19 | 4,580 | $883.94 | 118,549 | |
| Equels Thomas K | AIM | CEO & President | Dec 18 '24 | Buy | $0.21 | 22,727 | $4,681.76 | 1,680,695 | |
| APPELROUTH STEWART | AIM | Director | Dec 2 '24 | Buy | $0.21 | 11,112 | $2,355.74 | 344,398 | |
| Equels Thomas K | AIM | CEO & President | Nov 20 '24 | Buy | $0.19 | 145,110 | $27,915.13 | 1,680,695 | |
| APPELROUTH STEWART | AIM | Director | Nov 20 '24 | Buy | $0.19 | 81,953 | $15,816.93 | 344,398 |
Latest AIM ImmunoTech Inc. News
AIM Breaking Stock News: Dive into AIM Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
GlobeNewswire
a month ago
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
Business Wire
a month ago
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
Business Wire
a month ago
AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy Card
GlobeNewswire
a month ago
Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board
GlobeNewswire
a month ago
UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card
Business Wire
a month ago
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members
GlobeNewswire
a month ago
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
Compare AIM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AIM AIM ImmunoTech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.